Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC50H62ClN9O8S2 |
InChIKeySLPWRCRRHVRNRM-BEGQQDOQSA-N |
CAS Registry2409538-70-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United Kingdom | 27 Apr 2020 | |
Neoplasms | Preclinical | United Kingdom | 27 Apr 2020 |